<DOC>
	<DOC>NCT00675688</DOC>
	<brief_summary>The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.</brief_summary>
	<brief_title>Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Endometrial Hyperplasia</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<mesh_term>Estrogens, Conjugated (USP)</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Generally healthy, postmenopausal women aged 40 75 years inclusive Intact uterus Last natural menstrual cycle (without exogenous hormone therapy) completed at least 12 consecutive months before screening A history or active presence of thrombophlebitis, thrombosis or thromboembolic disorders A history or active presence of cerebrovascular accident, stroke, or transient ischemic attack A history or active presence of malignancy, or treatment for malignancy, within the previous 10 years Additional criteria applies.</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Menopause</keyword>
</DOC>